Clinical trials: CVD - Cardiovascular Disease
Acute Anterior Myocardial Infarction
Rapid Intravascular Cooling in Myocardial Infarction as Adjunctive to Percutaneous Coronary Intervention
Rapid MI-ICE-Pilot is designed to demonstrate the safety and efficacy of the Celsius Control™ System (CCS) endovascular catheter to reduce the infarct size resulting from acute anterior myocardial infarction when used in…
- Trial name
- NCT00417638
- Testing
- Endovascular cooling by the Celsius Control System, Standard of care
- Where
- Sweden
- Volunteers
- 20 people
- Sponsor
- ZOLL Circulation, Inc., USA
Acute Myocardial Infarction
TandemHeart to Reduce Infarct Size (TRIS Trial)
The purpose of this study is to determine if a device known as the TandemHeart® System (TandemHeart) can help limit heart damage and reduce serious complications after a certain type of heart attack (acute ST elevation anterior…
- Trial name
- TRIS (NCT02164058)
- Testing
- TandemHeart System, Percutaneous coronary intervention
- Sponsor
- CardiacAssist, Inc.
Stroke
The Evaluation of Safety, Tolerability and Pharmacokinetics of Stroke Targeting Drug in Healthy Volunteers
The purpose of this study in to evaluate safety, tolerability, pharmacokinetics of JPI-289 in healthy male subjects.
- Trial name
- JPI-289 (NCT01983358)
- Testing
- JPI-289
- Where
- South Korea
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Jeil Pharmaceutical Co., Ltd.
Hereditary Angioedema
A Phase III, Crossover Trial Evaluating the Efficacy and Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)
This study is a randomized, double-blind, placebo-controlled, phase III, three-way crossover clinical trial evaluating the efficacy and safety of KVD900, in the treatment of hereditary angioedema attacks in adolescent and adult…
- Trial name
- NCT05259917
- Testing
- KVD900 600 mg, KVD900 300 mg
- Where
- 66 sites in United States, Australia and 19 more
- Volunteers
- 136 people
- Sponsor
- KalVista Pharmaceuticals, Ltd.
Pulmonary Hypertension
LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF
This study will evaluate the efficacy of TNX-103 (oral levosimendan) compared with placebo in subjects with PH-HFpEF as measured by the change in 6-Minute Walk Distance (6 MWD; Day 1 to Week 12).
- Trial name
- LEVEL (NCT05983250)
- Testing
- TNX-103
- Where
- 42 sites in United States, Canada
- Volunteers
- 230 people
- Sponsor
- Tenax Therapeutics, Inc.
Heart Failure
BAROSTIM NEO System in the Treatment of Heart Failure
The purpose of this portion of study NCT01471860 is to assess the long-term safety and efficacy of the BAROSTIM NEO System in Canadian study participants implanted with the device.
- Trial name
- NCT01471860
- Testing
- BAROSTIM NEO System, Medical Management
- Where
- 30 sites in Canada, France and 2 more
- Volunteers
- 94 people
- Sponsor
- CVRx, Inc.
Hypertension, Diabetes Mellitus, Type 2
INV-144 Versus Losartan in Hypertension and Type 2 Diabetes Mellitus Patients With Macroalbuminuria
A randomized, double-blind, active control trial to determine the safety, efficacy and pharmacokinetics of INV-144 versus losartan potassium plus placebo in subjects with hypertension and Type 2 diabetes mellitus with nephropathy…
- Trial name
- NCT01398423
- Testing
- Active Control, INV-144
- Where
- 19 sites in United States
- Volunteers
- 88 people
- Sponsor
- InVasc Therapeutics, Inc.
Heart Failure
An Automated Continual Water Removal System in Patients With Advanced Diuretic Resistant Heart Failure
This study will assess the functionality and tolerability of an automated continual water removal system in up to 8 patients with HF and diuretic resistance.
- Trial name
- ACWR-HF (NCT05140759)
- Testing
- automated continual water removal system
- Where
- 3 sites in Georgia, Israel and 1 more
- Volunteers
- 3 people
- Sponsor
- Paragate Medical LTD
Relapsed and/or Refractory Multiple Myeloma
Study To Evaluate Safety and Efficacy of P276-00 in Subjects With Refractory Multiple Myeloma
The purpose of this study is to determine safety of P276-00 in patients with advanced multiple myeloma and whether P276-00 is effective in the treatment of advanced cases of multiple myeloma.
- Trial name
- NCT00882063
- Testing
- P276-00
- Where
- 5 sites in India
- Volunteers
- 19 people
- Sponsor
- Piramal Enterprises Limited
Acute Anterior Myocardial Infarction
The INFUSE - Anterior Myocardial Infarction (AMI) Study
This is a multicenter, open-label, controlled, single-blind, randomized study with up to 452 subjects enrolled in up to 50 US and European sites.
- Trial name
- NCT00976521
- Testing
- Abciximab local infusion, No local infusion, Thrombus aspiration
- Where
- 38 sites in United States, Austria and 4 more
- Volunteers
- 452 people
- Sponsor
- Atrium Medical Corporation
Hypertension
COREG MR Versus TOPROL-XL On The Lipid Profile Of Normolipidemic Or Mildly Dyslipidemic Patients With Hypertension
This study was designed to determine whether treatment with COREG MR is more effective at maintaining a better lipid profile than treatment with TOPROL-XL for hypertension.
- Trial name
- NCT00273052
- Testing
- Carvedilol Phosphate modified release formulation, metoprolol succinate
- Where
- 120 sites in United States, Canada and 1 more
- Volunteers
- 514 people
- Sponsor
- GlaxoSmithKline
Atherosclerotic Coronary Artery Disease
An Observational Safety Evaluation of Patients Treated With the NEVO™ Sirolimus-eluting Coronary Stent. (NEVO II)
As a result of the implementation of Protocol Am3.0, the design and objective of the NEVO II trial were changed to focus on the safety follow-up of the 103 NEVO™ subjects.
- Trial name
- NEVO II (NCT01202058)
- Testing
- NEVO™ Sirolimus-eluting Coronary Stent System, XIENCE V®/XIENCE PRIME™/PROMUS® Everolimus-eluting Coronary Stent System)
- Where
- 3 sites in Netherlands, Spain and 1 more
- Volunteers
- 156 people
- Sponsor
- Cordis US Corp.
Type 2 Diabetes Mellitus (T2DM), Cardiovascular Diseases
Bioequivalence Study to Compare Empagliflozin/Linagliptin/Metformin HCl25 mg/5 mg/1000 mg Extended Release Tablet Versus Trijardy® XR 25 mg/5 mg/1000 mg Extended- Release Tablets
An open label, randomized, two-period, two treatment, two-sequence, crossover, balanced, single dose oral bioequivalence study to compare Empagliflozin/ Linagliptin/ Metformin HCl 25 mg/5 mg/1000 mg Extended Release Tablet versus…
- Trial name
- NCT07872358
- Testing
- Empagliflozin/Linagliptin/Metformin HCl Extended Release Tablet, Trijardy® XR Tablets
- Where
- India
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Humanis Saglık Anonim Sirketi
Coronary Artery Disease
ARTDIVA Study : First in Man Safety Evaluation of the ART18Z Bioresorbable Stent
This prospective, multicentre, open labeled, single arm, first in man interventional investigation aims to evaluate the safety of the ART18Z bioresorbable stent for the treatment of patients with single de novo lesion of a native…
- Trial name
- NCT01761578
- Testing
- ART18Z Bioresorbable stent
- Where
- 5 sites in France
- Volunteers
- 30 people
- Sponsor
- Arterial Remodeling Technologies
Congenital Heart Disease
A Study to Evaluate MEDI-524 In Children With Hemodynamically Significant Congenital Heart Disease
The primary goal was to describe the safety of the investigational product when given monthly to prevent serious respiratory infection among children with significant heart disease.
- Trial name
- NCT00538785
- Testing
- Motavizumab, Palivizumab
- Where
- 152 sites in United States, Austria and 15 more
- Volunteers
- 1,236 people
- Sponsor
- MedImmune LLC
Arterio-Venous Fistula, ESRD
VasQ External Support for Arteriovenous Fistula
This is a prospective clinical study of the VasQ external support for arteriovenous fistulas. The device is designed to improve fistula outcomes by optimizing the geometrical configuration of the fistula, influencing…
- Conditions
- Arterio-Venous Fistula, ESRD, Steal Syndrome, Aneurysm
- Trial name
- NCT03242343
- Testing
- VasQ
- Where
- 15 sites in United States
- Volunteers
- 144 people
- Sponsor
- Laminate Medical Technologies
Carotid Artery Stenosis
Prospective Trial of IVL for Calcified Carotid Lesions(CREATE Trial)
Clinical Trial Summary Trial Title:** CREATE Trial: Safety and Efficacy of IVL for Carotid Calcified Lesions Sponsor:** Shanghai Bluesail Boyuan Medical Technology Co., Ltd.
- Trial name
- CREATE (NCT06936176)
- Testing
- Neurovascular Intravascular Shockwave Catheter
- Where
- China
- Volunteers
- 204 people
- Sponsor
- Shanghai Bluesail Boyuan Medical Technology Co., Ltd.
Acute Ischemic Stroke
Study of the KPCXM18 Injection for Treatment of Acute Ischemic Stroke
This study is a multicenter, randomized, double-blind, parallel, placebo-controlled trial design to evaluate the efficacy and safety of the KPCXM18 injection at different doses for the treatment of acute ischemic stroke and its…
- Trial name
- NCT05745311
- Testing
- The KPCXM18 injection
- Volunteers
- 240 people
- Sponsor
- Kunming Pharmaceuticals, Inc.
Stable Coronary Artery Disease
A Study of the Antiplatelet Effects Comparing Ticagrelor (Ticag. - AZD6140) With Clopidogrel (Clop.) Responder and Non-responders
The purpose of this study is to see how Ticagrelor, a new oral reversible anti-platelet medication, affects platelets. Anti-platelet agents are medications that block the formation of blood clots by preventing the clumping of…
- Trial name
- RESPOND (NCT00642811)
- Testing
- Ticagrelor, Clopidogrel, Aspirin
- Where
- 10 sites in United States, Canada and 2 more
- Volunteers
- 98 people
- Sponsor
- AstraZeneca
Diabetic Foot Ulcers
Safety Evaluation of the KLOX BioPhotonic System in Diabetic Foot Ulcers
The primary objective of these case series is to evaluate the safety and tolerability of the KLOX BioPhotonic System as adjunctive therapy to Standard Of Care (SOC) in patients with diabetic foot ulcers.
- Trial name
- NCT02222506
- Testing
- KLOX BioPhotonic System
- Where
- 3 sites in Canada
- Volunteers
- 10 people
- Sponsor
- KLOX Technologies Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.